Drugs / Omega 3 pentaenoic acid
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04177680 | Jun → Nov 2020 | hypertriglyceridemia | Matinas BioPharma Nanotechnologies, Inc. | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Omega 3 pentaenoic acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04177680 ↗ |
| Route | Oral | “2g MAT9001 capsules twice daily with meals” NCT04177680 ↗ |